TMCnet News
Imperva (IMPV)Alert: Johnson Fistel Investigates Proposed Sale of Imperva, Inc.; Is $55.75 a Fair Price?SAN DIEGO, Oct. 10, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Imperva, Inc. ("Imperva") (NASDAQ: IMPV) breached their fiduciary duties in connection with the proposed sale of the Company to Thoma Bravo, LLC ("Thoma Bravo). On October 10, 2018, Imperva announced that it had signed a definitive merger agreement with Thoma Bravo. Under the terms of the transaction, Imperva shareholders will receive $55.75 a share per share in cash for each share of Imperva held. The investigation concerns whether the Imperva board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Imperva shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given one Wall Street analyst has a $65.00 price target on the stock. If you are a shareholder of Imperva and believe the proposed buyout price is too low o you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number. Additionally, you can [Click here to join this action]. There is no cost or obligation to you. About Johnson Fistel, LLP: Contact: [Click here to join this action]
SOURCE Johnson Fistel, LLP 
|
View original content: